266 related articles for article (PubMed ID: 34323648)
1. Progression-free survival in patients with
Werensteijn-Honingh AM; Wevers AFJ; Peters M; Kroon PS; Intven M; Eppinga WSC; Jürgenliemk-Schulz IM
Acta Oncol; 2021 Oct; 60(10):1342-1351. PubMed ID: 34323648
[TBL] [Abstract][Full Text] [Related]
2. Metastasis-directed Therapy (SBRT) Guided by PET-CT
Mazzola R; Francolini G; Triggiani L; Napoli G; Cuccia F; Nicosia L; Livi L; Magrini SM; Salgarello M; Alongi F
Clin Genitourin Cancer; 2021 Jun; 19(3):230-236. PubMed ID: 32863189
[TBL] [Abstract][Full Text] [Related]
3. Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers.
Kwon DH; Shakhnazaryan N; Shui D; Hong JC; Mohamad O; de Kouchkovsky I; Borno HT; Bose R; Chou J; Desai A; Fong L; Friedlander TW; Koshkin VS; Aggarwal RR; Feng FY; Hope TA; Small EJ
Urol Oncol; 2023 Mar; 41(3):145.e7-145.e15. PubMed ID: 36435709
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic radiotherapy to oligoprogressive lesions detected with
Onal C; Ozyigit G; Oymak E; Guler OC; Tilki B; Hurmuz P; Akyol F
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3683-3692. PubMed ID: 33693965
[TBL] [Abstract][Full Text] [Related]
5. 68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer.
Kalinauskaite G; Senger C; Kluge A; Furth C; Kufeld M; Tinhofer I; Budach V; Beck M; Hochreiter A; Grün A; Stromberger C
PLoS One; 2020; 15(10):e0240892. PubMed ID: 33085712
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy.
Henkenberens C; Oehus AK; Derlin T; Bengel F; Ross TL; Kuczyk MA; Janssen S; Christiansen H; von Klot CAJ
Strahlenther Onkol; 2020 Nov; 196(11):1006-1017. PubMed ID: 32399639
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic Radiotherapy for Lesions Detected via
Pan J; Wei Y; Zhang T; Liu C; Hu X; Zhao J; Gan H; Liu W; Zhu B; Wu J; Wang B; Song S; Ye D; Zhu Y
Eur Urol Oncol; 2022 Aug; 5(4):420-427. PubMed ID: 35304107
[TBL] [Abstract][Full Text] [Related]
8. Treatment outcomes of metastasis-directed treatment using
Hurmuz P; Onal C; Ozyigit G; Igdem S; Atalar B; Sayan H; Akgun Z; Kurt M; Ozkok HB; Selek U; Oymak E; Tilki B; Guler OC; Mustafayev TZ; Saricanbaz I; Rzazade R; Akyol F
Strahlenther Onkol; 2020 Nov; 196(11):1034-1043. PubMed ID: 32617620
[TBL] [Abstract][Full Text] [Related]
9. Oligometastatic Bone Disease in Castration-Sensitive Prostate Cancer Patients Treated With Stereotactic Body Radiotherapy Using 68Ga-PSMA PET/CT: TROD 09-004 Study.
Onal C; Ozyigit G; Akgun Z; Atalar B; Igdem S; Oymak E; Agaoglu F; Selek U; Guler OC; Hurmuz P; Mustafayev TZ; Akyol F
Clin Nucl Med; 2021 Jun; 46(6):465-470. PubMed ID: 33661210
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
[TBL] [Abstract][Full Text] [Related]
11. Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT.
Bouman-Wammes EW; van Dodewaard-De Jong JM; Dahele M; Cysouw MCF; Hoekstra OS; van Moorselaar RJA; Piet MAH; Verberne HJ; Bins AD; Verheul HMW; Slotman BJ; Oprea-Lager DE; Van den Eertwegh AJM
Clin Genitourin Cancer; 2017 Oct; 15(5):e773-e782. PubMed ID: 28462855
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer : An investigation of 117 pelvic lymph nodes.
Cozzi S; Botti A; Timon G; Blandino G; Najafi M; Manicone M; Bardoscia L; Ruggieri MP; Ciammella P; Iotti C
Strahlenther Onkol; 2022 Aug; 198(8):700-709. PubMed ID: 34757443
[TBL] [Abstract][Full Text] [Related]
13.
Marzec J; Becker J; Paulsen F; Wegener D; Olthof SC; Pfannenberg C; Schwenck J; Bedke J; Stenzl A; Nikolaou K; la Fougère C; Zips D; Müller AC
Acta Oncol; 2020 Feb; 59(2):149-156. PubMed ID: 31559880
[No Abstract] [Full Text] [Related]
14. PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: a multi-institutional study.
Mazzola R; Cuccia F; Pastorello E; Salgarello M; Francolini G; Livi L; Triggiani L; Magrini SM; Ingrosso G; Aristei C; Franzese C; Scorsetti M; Alongi F
Clin Exp Metastasis; 2022 Jun; 39(3):443-448. PubMed ID: 35266063
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiotherapy (SBRT) versus androgen deprivation therapy (ADT) for oligometastatic prostate cancer: protocol for a prospective randomised control clinical trial.
Zhao X; Wang T; Ye Y; Li J; Gao X; Zhang H
BMJ Open; 2022 Sep; 12(9):e051371. PubMed ID: 36180115
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic Body Radiotherapy for Lymph-Nodal Oligometastatic Prostate Cancer: A Multicenter Retrospective Experience.
Cuccia F; Tamburo M; Piras A; Mortellaro G; Iudica A; Daidone A; Federico M; Zagardo V; Ferini G; Marletta F; Spatola C; Fazio I; Filosto S; Pergolizzi S; Ferrera G
Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629732
[No Abstract] [Full Text] [Related]
17. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer.
Mohan R; Kneebone A; Eade T; Hsiao E; Emmett L; Brown C; Hunter J; Hruby G
Radiat Oncol; 2023 Aug; 18(1):127. PubMed ID: 37528487
[TBL] [Abstract][Full Text] [Related]
19. How accurate is
Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
[TBL] [Abstract][Full Text] [Related]
20. Metabolic response after 68Ga-PSMA-PET/CT-directed IGRT/SBRT for oligometastases prostate cancer.
Gawish A; Abdullayev N; El-Arayedh S; Röllich B; Ochel HJ; Brunner TB
Clin Transl Oncol; 2023 Apr; 25(4):987-994. PubMed ID: 36369631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
